Raymond James Cuts Quest Diagnostics to Underperform (DGX)

By admin | 6 years ago

Quest Diagnostics (NYSE: DGX) was downgraded by research analysts at Raymond James (NYSE: RJF) from an “outperform” rating to an “underperform” rating in a report released on Wednesday.

Shares of Quest Diagnostics traded up 0.95% during mid-day trading on Wednesday, hitting $55.16. Quest Diagnostics has a 52 week low of $45.13 and a 52 week high of $62.32. The company has a market cap of $8.751 billion and a P/E ratio of 12.84.

Quest Diagnostics last announced its earnings results on Wednesday, April 18th. The company reported $1.07 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.01 by $0.06. The company’s quarterly revenue was up 6.3% on a year-over-year basis. On average, analysts predict that Quest Diagnostics will post $1.20 earnings per share next quarter.

A number of other analysts have also recently weighed in on DGX. Analysts at Zacks reiterated a “neutral” rating on shares of Quest Diagnostics in a research note to investors on Thursday, April 19th. They now have a $62.00 price target on the stock. Analysts at Bank of America (NYSE: BAC) raised their price target on shares of Quest Diagnostics from $60.00 to $61.00 in a research note to investors on Wednesday, April 18th. They now have a “buy” rating on the stock.

Quest Diagnostics Incorporated is a provider of diagnostic testing, information and services. It offers diagnostic testing services and products to patients, physicians, payers, and others.

About the author